Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset

Merck KGaA (Germany) plans to acquire Silence Therapeutics, a UK-based biotech company, to strengthen its rare disease pipeline. The acquisition focuses on Divesiran, an siRNA therapy for polycythemia vera that met its primary endpoint in a Phase 2 trial, with an 88% responder rate. The deal is expected to close in Q1 2027, subject to regulatory approvals and shareholder approval. Merck will fund the acquisition through new debt.

Original reporting
Published Oct 19, 2026, 12:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 12:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics, Strengthening Rare Disease Pipeline with Innovative siRNA Asset — source image
Decision brief

The 30-second read

Med
01

Why it matters

The acquisition expands Merck's rare‑disease pipeline and adds a potentially best‑in‑class therapy, likely influencing Merck's valuation and sector sentiment.

02

Market read

A major M&A move in the biotech space that could shift investor focus toward rare‑disease therapeutics.

03

What to watch

Regulatory approval risk and integration challenges for a German pharma acquiring a UK biotech.

Relevance 8/10Novelty 8/10Timing: today

Background

Merck KGaA announced a planned acquisition of Silence Therapeutics, a UK‑based biotech with an ADS listed on NASDAQ, to acquire its siRNA asset Divesiran.

Market effects

Potential boost to biotech and rare disease sector as Merck KGaA expands its siRNA pipeline.

European pharma market may see increased M&A activity following this deal.

Global investors may reprice other rare‑disease biotech stocks.

Counterpoint

Deal could be overvalued if Phase 3 data for Divesiran fails to meet expectations.

Key entities

  • Merck KGaA

    German science and technology company acquiring Silence Therapeutics.

  • Silence Therapeutics

    UK biotech with siRNA asset Divesiran, listed via ADS on NASDAQ.

Related articles

$MRKHigh

Why Merck (MRK) Stock Is Down Today

Merck (MRK) shares fell 3.8% after the company discontinued the BELLWAVE clinical program for nemtabrutinib, citing potential risks outweighing benefits in a Phase 3 trial. The decision impacts multiple studies, marking a pipeline setback for the drugmaker. Merck's latest earnings report had shown revenue growth and pipeline activity before this development.

$MRKHigh

Merck wins all 14 U.S. patent reviews against Halozyme

Merck (MSD) won all 14 U.S. patent reviews against Halozyme, securing its Keytruda Qlex cancer immunotherapy's subcutaneous injection technology. The Patent Trial and Appeal Board ruled all challenged claims unpatentable. Keytruda Qlex sales reached $830M in Q3, 9.7% of total Keytruda sales. Halozyme may appeal, and a patent infringement lawsuit is ongoing.